RIP1 is required for IAP inhibitor-mediated sensitization for TRAIL-induced apoptosis via a RIP1/FADD/caspase-8 cell death complex

Oncogene

Volumn 32, Issue 27, 2013, Pages 3263-3273

  Abhari, B A ^a   Cristofanon, S ^a   Kappler, R ^b   Von Schweinitz, D ^b   Humphreys, R ^c   Fulda, S ^a  

^a GOETHE UNIVERSITY   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Apoptosis; IAP inhibitor; Neuroblastoma; RIP1; TRAIL

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; ETANERCEPT; FAS ASSOCIATED DEATH DOMAIN PROTEIN; GAMMA INTERFERON; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEXATUMUMAB; MAPATUMUMAB; NECROSTATIN 1; PROTEIN BID; PROTEIN KINASE; RIP1 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; IMMUNOPRECIPITATION; IN VITRO STUDY; NEUROBLASTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CASPASE 8; CELL LINE, TUMOR; DRUG SYNERGISM; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME INHIBITORS; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; HUMANS; IMMUNOPRECIPITATION; INHIBITOR OF APOPTOSIS PROTEINS; NUCLEAR PORE COMPLEX PROTEINS; RNA INTERFERENCE; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84880265865     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.337     Document Type: Article

References (41)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
2. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006; 25: 4798-4811.
3. Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 2008; 7: 1001-1012.
4. Fulda S, Galluzzi L, Kroemer G. Targeting mitochondria for cancer therapy. Nat Rev Drug Discov 2010; 9: 447-464.
5. Fulda S. Tumor resistance to apoptosis. Int J Cancer 2009; 124: 511-515.
6. LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk RG. IAP-targeted therapies for cancer. Oncogene 2008; 27: 6252-6275.
7. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 2007; 131: 669-681.
8. Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007; 131: 682-693.
9. Bertrand MJ, Milutinovic S, Dickson KM, Ho WC, Boudreault A, Durkin J et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 2008; 30: 689-700.
10. Varfolomeev E, Goncharov T, Fedorova AV, Dynek JN, Zobel K, Deshayes K et al. c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)- induced NF-kappaB activation. J Biol Chem 2008; 283: 24295-24299.
11. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007; 369: 2106-2120.
12. Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2L/TRAILor anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 2002; 8: 808-815.
13. Straub CS. Targeting IAPs as an approach to anti-cancer therapy. Curr Top Med Chem 2011; 11: 291-316.
14. Smith MA, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H et al. Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program. Pediatr Blood Cancer 2010; 54: 307-310.
15. Houghton PJ, Kang MH, Reynolds CP, Morton CL, Kolb EA, Gorlick R et al. Initial testing (stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing program. Pediatr Blood Cancer 2012; 58: 636-639.
16. Fulda S, Poremba C, Berwanger B, Hacker S, Eilers M, Christiansen H et al. Loss of caspase-8 expression does not correlate with MYCN amplification, aggressive disease, or prognosis in neuroblastoma. Cancer Res 2006; 66: 10016-10023.
17. Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 2000; 6: 529-535.
18. Stadel D, Mohr A, Ref C, MacFarlane M, Zhou S, Humphreys R et al. TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors. Clin Cancer Res 2010; 16: 5734-5749.
19. Naumann I, Kappler R, von Schweinitz D, Debatin KM, Fulda S. Bortezomib primes neuroblastoma cells for TRAIL-induced apoptosis by linking the death receptor to the mitochondrial pathway. Clin Cancer Res 2011; 17: 3204-3218.
20. He S, Wang L, Miao L, Wang T, Du F, Zhao L et al. Receptor interacting protein kinase-3 (RIP3) determines cellular necrotic response to TNFa. Cell 2009; 137: 1100-1111.
21. Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 2005; 1: 112-119.
22. Petersen SL, Wang L, Yalcin-Chin A, Li L, Peyton M, Minna J et al. Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimeticinduced apoptosis. Cancer Cell 2007; 12: 445-456.
23. Wang L, Du F, Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell 2008; 133: 693-703.
24. Biton S, Ashkenazi ANEMO. and RIP1 control cell fate in response to extensive DNA damage via TNF-alpha feedforward signaling. Cell 2011; 145: 92-103.
25. Tenev T, Bianchi K, Darding M, Broemer M, Langlais C, Wallberg F et al. The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol Cell 2011; 43: 432-448.
26. Feoktistova M, Geserick P, Kellert B, Dimitrova DP, Langlais C, Hupe M et al. cIAPs block Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. Mol Cell 2011; 43: 449-463.
27. Palacios C, Lopez-Perez AI, Lopez-Rivas A. Down-regulation of RIP expression by 17-dimethylaminoethylamino-17-demethoxygeldanamycin promotes TRAILinduced apoptosis in breast tumor cells. Cancer Lett 2010; 287: 207-215.
28. Bellail AC, Tse MC, Song JH, Phuphanich S, Olson JJ, Sun SY et al. DR5-mediated DISC controls caspase-8 cleavage and initiation of apoptosis in human glioblastomas. J Cell Mol Med 2010; 14: 1303-1317.
29. Festjens N, Vanden Berghe T, Cornelis S, Vandenabeele P. RIP1 a kinase on the crossroads of a cell's decision to live or die. Cell Death Differ 2007; 14: 400-410.
30. Vandenabeele P, Galluzzi L, Vanden Berghe T, Kroemer G. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol 2010; 11: 700-714.
31. Vanlangenakker N, Vanden Berghe T, Bogaert P, Laukens B, Zobel K, Deshayes K et al. cIAP1 and TAK1 protect cells from TNF-induced necrosis by preventing RIP1/RIP3- dependent reactive oxygen species production. Cell Death Differ 2011; 18: 656-665.
32. Laukens B, Jennewein C, Schenk B, Vanlangenakker N, Schier A, Cristofanon S et al. Smac mimetic bypasses apoptosis resistance in FADD- or caspase-8-deficient cells by priming for tumor necrosis factor alpha-induced necroptosis. Neoplasia 2011; 13: 971-979.
33. Geserick P, Hupe M, Moulin M, Wong WW, Feoktistova M, Kellert B et al. Cellular IAPs inhibit a cryptic CD95-induced cell death by limiting RIP1 kinase recruitment. J Cell Biol 2009; 187: 1037-1054.
34. Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 1997; 57: 3823-3829.
35. Humphreys RC, Halpern W. Trail receptors: targets for cancer therapy. Adv Exp Med Biol 2008; 615: 127-158.
36. Oost TK, Sun C, Armstrong RC, Al-Assaad AS, Betz SF, Deckwerth TL et al. Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J Med Chem 2004; 47: 4417-4426.
37. Chao B, Deckwerth TL, Furth PS, Linton SD, Spada AP, Ullman BR et al. inventors; Tetrapeptide analogs. United States patent PCT/US2005/024700 2006; 16: 02.
38. Loeder S, Fakler M, Schoeneberger H, Cristofanon S, Leibacher J, Vanlangenakker N et al. RIP1 is required for IAP inhibitor-mediated sensitization of childhood acute leukemia cells to chemotherapy-induced apoptosis. Leukemia 2012; 26: 1020-1029.
39. Mader I, Wabitsch M, Debatin KM, Fischer-Posovszky P, Fulda S. Identification of a novel proapoptotic function of resveratrol in fat cells: SIRT1-independent sensitization to TRAIL-induced apoptosis. FASEB J 2010; 24: 1997-2009.
40. Karl S, Pritschow Y, Volcic M, Hacker S, Baumann B, Wiesmuller L et al. Identification of a novel pro-apopotic function of NF-kappaB in the DNA damage response. J Cell Mol Med 2009; 13: 4239-4256.
41. Chou TC. The median-effect principle and the combination index for quantitation of synergism and antagonism. In: Chou TC (ed.) Synergism and Antagonism in Chemotherapy. Academic Press: San Diego, USA, 1991, p 61-102.